 Enlivex Therapeutics Ltd. ENLV, a clinical-stage immunotherapy company, today announced that new analyses from its recently completed Phase Ib clinical trial of AllocetraTM in patients with sepsis will be presented as part of an oral presentation at the International Society for Cellular Therapy ISCT 2020 Paris-Virtual Annual Meeting at a plenary satellite entitled Moving ahead at full speed: Immune-Mediated Therapeutics. The presentation will include new exploratory endpoint analyses that demonstrated the potential of AllocetraTM to resolve cytokine storms with heterogenous underlying pathologies, as well as previously disclosed safety and efficacy data. 